miR186 suppresses prostate cancer progression by targeting Twist1

Oncotarget

Volumn 7, Issue 22, 2016, Pages 33136-33151

  Zhao, Xian ^a   Wang, Yanli ^a   Deng, Rong ^a   Zhang, Hailong ^a   Dou, Jinzhuo ^a   Yuan, Haihua ^a   Hou, Guofang ^a   Du, Yuzhang ^a   Chen, Qin ^a   Yu, Jianxiu ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Metastasis; microRNA (miRNA); miR186; Prostate cancer (PCa); Twist1

Indexed keywords

MESSENGER RNA; MICRORNA; PROTEIN TWIST1; TRANSCRIPTION FACTOR TWIST; UNCLASSIFIED DRUG; MIRN186 MICRORNA, HUMAN; NUCLEAR PROTEIN; TWIST RELATED PROTEIN 1; TWIST1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER SURVIVAL; CANCER TISSUE; CELL INVASION; CELL MIGRATION; CELL MOTILITY; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; IN VIVO STUDY; M12 CELL LINE; MALE; METASTASIS; MOUSE; NONHUMAN; PHENOTYPE; PLASMID; PROSTATE CANCER; PROSTATE CANCER CELL LINE; REAL TIME POLYMERASE CHAIN REACTION; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; DISEASE EXACERBATION; GENETICS; METABOLISM; PATHOLOGY; PROSTATE TUMOR; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

CELL LINE, TUMOR; DISEASE PROGRESSION; DOWN-REGULATION; HUMANS; MALE; MICRORNAS; NUCLEAR PROTEINS; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TWIST-RELATED PROTEIN 1;

EID: 84973565850     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8887     Document Type: Article

References (39)

1. Arya M, Bott SR, Shergill IS, Ahmed HU, Williamson M and Patel HR. The metastatic cascade in prostate cancer. Surg Oncol. 2006; 15:117-128.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009; 59:225-249.
3. Denmeade SR and Isaacs JT. Development of prostate cancer treatment: the good news. The Prostate. 2004; 58:211-224.
4. Valastyan S and Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011; 147:275-292.
5. Taube JH, Herschkowitz JI, Komurov K, Zhou AY, Gupta S, Yang J, Hartwell K, Onder TT, Gupta PB, Evans KW, Hollier BG, Ram PT, Lander ES, Rosen JM, Weinberg RA and Mani SA. Core epithelial-tomesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proceedings of the National Academy of Sciences of the United States of America. 2010; 107:15449-15454.
6. Singh A and Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010; 29:4741-4751.
7. Polyak K and Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nature reviews Cancer. 2009; 9:265-273.
8. Huber MA, Kraut N and Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol. 2005; 17:548-558.
9. Kwok WK, Ling MT, Lee TW, Lau TC, Zhou C, Zhang X, Chua CW, Chan KW, Chan FL, Glackin C, Wong YC and Wang X. Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target. Cancer research. 2005; 65:5153-5162.
10. Wang X, Ling MT, Guan XY, Tsao SW, Cheung HW, Lee DT and Wong YC. Identification of a novel function of TWIST, a bHLH protein, in the development of acquired taxol resistance in human cancer cells. Oncogene. 2004; 23:474-482.
11. Chen CZ, Li L, Lodish HF and Bartel DP. MicroRNAs modulate hematopoietic lineage differentiation. Science. 2004; 303:83-86.
12. Kim VN. MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol. 2005; 6:376-385.
13. Iorio MV and Croce CM. microRNA involvement in human cancer. Carcinogenesis. 2012; 33:1126-1133.
14. Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, Teruya-Feldstein J, Reinhardt F, Onder TT, Valastyan S, Westermann F, Speleman F, Vandesompele J and Weinberg RA. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nature cell biology. 2010; 12:247-256.
15. Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S and Brabletz T. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep. 2008; 9:582-589.
16. Park SM, Gaur AB, Lengyel E and Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 2008; 22:894-907.
17. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y and Goodall GJ. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nature cell biology. 2008; 10:593-601.
18. Bae VL, Jackson-Cook CK, Brothman AR, Maygarden SJ and Ware JL. Tumorigenicity of SV40 T antigen immortalized human prostate epithelial cells: association with decreased epidermal growth factor receptor (EGFR) expression. International journal of cancer. 1994; 58:721-729.
19. Bae VL, Jackson-Cook CK, Maygarden SJ, Plymate SR, Chen J and Ware JL. Metastatic sublines of an SV40 large T antigen immortalized human prostate epithelial cell line. The Prostate. 1998; 34:275-282.
20. Liu X, Chen Q, Yan J, Wang Y, Zhu C, Chen C, Zhao X, Xu M, Sun Q, Deng R, Zhang H, Qu Y, Huang J, Jiang B and Yu J. MiRNA-296-3p-ICAM-1 axis promotes metastasis of prostate cancer by possible enhancing survival of natural killer cell-resistant circulating tumour cells. Cell death & disease. 2013; 4:e928.
21. Xu M, Zhu C, Zhao X, Chen C, Zhang H, Yuan H, Deng R, Dou J, Wang Y, Huang J, Chen Q, Jiang B and Yu J. Atypical ubiquitin E3 ligase complex Skp1-Pam-Fbxo45 controls the core epithelial-to-mesenchymal transitioninducing transcription factors. Oncotarget. 2015; 6:979-994. doi: 10.18632/oncotarget.2825.
22. Shiota M, Yokomizo A, Tada Y, Inokuchi J, Kashiwagi E, Masubuchi D, Eto M, Uchiumi T and Naito S. Castration resistance of prostate cancer cells caused by castrationinduced oxidative stress through Twist1 and androgen receptor overexpression. Oncogene. 2010; 29:237-250.
23. Pang Y, Young CY and Yuan H. MicroRNAs and prostate cancer. Acta biochimica et biophysica Sinica. 2010; 42:363-369.
24. Cai J, Wu J, Zhang H, Fang L, Huang Y, Yang Y, Zhu X, Li R and Li M. miR-186 downregulation correlates with poor survival in lung adenocarcinoma, where it interferes with cell-cycle regulation. Cancer research. 2013; 73:756-766.
25. Li H, Yin C, Zhang B, Sun Y, Shi L, Liu N, Liang S, Lu S, Liu Y, Zhang J, Li F, Li W, Liu F, Sun L and Qi Y. PTTG1 promotes migration and invasion of human nonsmall cell lung cancer cells and is modulated by miR-186. Carcinogenesis. 2013.
26. Myatt SS, Wang J, Monteiro LJ, Christian M, Ho KK, Fusi L, Dina RE, Brosens JJ, Ghaem-Maghami S and Lam EW. Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer. Cancer research. 2010; 70:367-377.
27. Maestro R, Dei Tos AP, Hamamori Y, Krasnokutsky S, Sartorelli V, Kedes L, Doglioni C, Beach DH and Hannon GJ. Twist is a potential oncogene that inhibits apoptosis. Genes Dev. 1999; 13:2207-2217.
28. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A and Weinberg RA. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 2004; 117:927-939.
29. Sun T, Zhao N, Zhao XL, Gu Q, Zhang SW, Che N, Wang XH, Du J, Liu YX and Sun BC. Expression and functional significance of Twist1 in hepatocellular carcinoma: its role in vasculogenic mimicry. Hepatology. 2010; 51:545-556.
30. Hoek K, Rimm DL, Williams KR, Zhao H, Ariyan S, Lin A, Kluger HM, Berger AJ, Cheng E, Trombetta ES, Wu T, Niinobe M, Yoshikawa K, Hannigan GE and Halaban R. Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer research. 2004; 64:5270-5282.
31. Entz-Werle N, Stoetzel C, Berard-Marec P, Kalifa C, Brugiere L, Pacquement H, Schmitt C, Tabone MD, Gentet JC, Quillet R, Oudet P, Lutz P, Babin-Boilletot A, Gaub MP and Perrin-Schmitt F. Frequent genomic abnormalities at TWIST in human pediatric osteosarcomas. International journal of cancer. 2005; 117:349-355.
32. Rosivatz E, Becker I, Specht K, Fricke E, Luber B, Busch R, Hofler H and Becker KF. Differential expression of the epithelial-mesenchymal transition regulators snail, SIP1, and twist in gastric cancer. Am J Pathol. 2002; 161:1881-1891.
33. Watanabe O, Imamura H, Shimizu T, Kinoshita J, Okabe T, Hirano A, Yoshimatsu K, Konno S, Aiba M and Ogawa K. Expression of twist and wnt in human breast cancer. Anticancer research. 2004; 24:3851-3856.
34. Zhu X, Shen H, Yin X, Long L, Xie C, Liu Y, Hui L, Lin X, Fang Y, Cao Y, Xu Y, Li M, Xu W and Li Y. miR-186 regulation of Twist1 and ovarian cancer sensitivity to cisplatin. Oncogene. 2015.
35. Limame R, Wouters A, Pauwels B, Fransen E, Peeters M, Lardon F, De Wever O and Pauwels P. Comparative analysis of dynamic cell viability, migration and invasion assessments by novel real-time technology and classic endpoint assays. PLoS One. 2012; 7:e46536.
36. Qu Y, Chen Q, Lai X, Zhu C, Chen C, Zhao X, Deng R, Xu M, Yuan H, Wang Y, Yu J and Huang J. SUMOylation of Grb2 enhances the ERK activity by increasing its binding with Sos1. Molecular cancer. 2014; 13:95.
37. Liu X, Wang Y, Sun Q, Yan J, Huang J, Zhu S and Yu J. Identification of microRNA transcriptome involved in human natural killer cell activation. Immunology letters. 2012; 143:208-217.
38. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, Barbisin M, Xu NL, Mahuvakar VR, Andersen MR, Lao KQ, Livak KJ and Guegler KJ. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 2005; 33:e179.
39. Huang J, Yan J, Zhang J, Zhu S, Wang Y, Shi T, Zhu C, Chen C, Liu X, Cheng J, Mustelin T, Feng GS, Chen G and Yu J. SUMO1 modification of PTEN regulates tumorigenesis by controlling its association with the plasma membrane. Nature communications. 2012; 3:911.